Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.

MLA

Barbanti, Piero, et al. “Early and Sustained Efficacy of Fremanezumab over 24-Weeks in Migraine Patients with Multiple Preventive Treatment Failures: The Multicenter, Prospective, Real-Life FRIEND2 Study.” The Journal of Headache and Pain, vol. 24, no. 1, Mar. 2023, p. 30. EBSCOhost, https://doi.org/10.1186/s10194-023-01561-w.

APA

Barbanti, P., Egeo, G., Aurilia, C., Torelli, P., Finocchi, C., d’Onofrio, F., d’Onofrio, L., Rao, R., Messina, S., Di Clemente, L., Ranieri, A., Autunno, M., Sette, G., Colombo, B., Carnevale, A., Aguggia, M., Tasillo, M., Zoroddu, F., Frediani, F., … Bonassi, S. (2023). Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. The Journal of Headache and Pain, 24(1), 30. https://doi.org/10.1186/s10194-023-01561-w

Chicago

Barbanti, Piero, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, et al. 2023. “Early and Sustained Efficacy of Fremanezumab over 24-Weeks in Migraine Patients with Multiple Preventive Treatment Failures: The Multicenter, Prospective, Real-Life FRIEND2 Study.” The Journal of Headache and Pain 24 (1): 30. doi:10.1186/s10194-023-01561-w.